Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2018
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2018
SUMMARY
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 3 - Pipeline Review, H2 2018, outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 5 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Relapsed Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Lymphoma, Mantle Cell Lymphoma, Melanoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Non-Hodgkin Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Alopecia, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Central Nervous System (CNS) Tumor, CNS Lymphoma, Cutaneous T-Cell Lymphoma, Drug Addiction, Endometrial Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Natural Killer Cell Lymphomas, Neuroblastoma, Neurodegenerative Diseases, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Soft Tissue Sarcoma, Thyroid Cancer and Unspecified.
Furthermore, this report also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 3 - Pipeline Review, H2 2018, outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 5 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Relapsed Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Lymphoma, Mantle Cell Lymphoma, Melanoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Non-Hodgkin Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Alopecia, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Central Nervous System (CNS) Tumor, CNS Lymphoma, Cutaneous T-Cell Lymphoma, Drug Addiction, Endometrial Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Natural Killer Cell Lymphomas, Neuroblastoma, Neurodegenerative Diseases, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Soft Tissue Sarcoma, Thyroid Cancer and Unspecified.
Furthermore, this report also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4D Pharma PLC
4SC AG
AlfaSigma SpA
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
Medivir AB
Merck & Co Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles
4SC-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDAC-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRx-0029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Aug 02, 2018: Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Basal Cell Carcinoma
Jul 31, 2018: 4SC announce first patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma
Jul 03, 2018: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma
Jun 18, 2018: Continued Discussions With FDA on Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Jun 04, 2018: HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors
May 31, 2018: Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
May 29, 2018: Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint
May 18, 2018: Additional Remetinostat Phase II Data Will be Presented at the International Investigative Dermatology Meeting on May 18 and
May 17, 2018: Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Apr 25, 2018: Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
Apr 20, 2018: Cumming researchers develop new method to discover drugs to treat epilepsy
Apr 16, 2018: Syndax to Present on Entinostat at the 2018 American Association for Cancer Research Annual Meeting
Jan 10, 2018: Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4D Pharma PLC
4SC AG
AlfaSigma SpA
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
Medivir AB
Merck & Co Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles
4SC-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDAC-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRx-0029 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Aug 02, 2018: Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Basal Cell Carcinoma
Jul 31, 2018: 4SC announce first patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma
Jul 03, 2018: Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma
Jun 18, 2018: Continued Discussions With FDA on Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
Jun 04, 2018: HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors
May 31, 2018: Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
May 29, 2018: Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint
May 18, 2018: Additional Remetinostat Phase II Data Will be Presented at the International Investigative Dermatology Meeting on May 18 and
May 17, 2018: Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Apr 25, 2018: Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
Apr 20, 2018: Cumming researchers develop new method to discover drugs to treat epilepsy
Apr 16, 2018: Syndax to Present on Entinostat at the 2018 American Association for Cancer Research Annual Meeting
Jan 10, 2018: Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by 4D Pharma PLC, H2 2018
Pipeline by 4SC AG, H2 2018
Pipeline by AlfaSigma SpA, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by Curis Inc, H2 2018
Pipeline by HitGen LTD, H2 2018
Pipeline by Medivir AB, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Syndax Pharmaceuticals Inc, H2 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by 4D Pharma PLC, H2 2018
Pipeline by 4SC AG, H2 2018
Pipeline by AlfaSigma SpA, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by Curis Inc, H2 2018
Pipeline by HitGen LTD, H2 2018
Pipeline by Medivir AB, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Syndax Pharmaceuticals Inc, H2 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
4D Pharma PLC
4SC AG
AlfaSigma SpA
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
Medivir AB
Merck & Co Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
4D Pharma PLC
4SC AG
AlfaSigma SpA
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
Medivir AB
Merck & Co Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
